entertainment -WSS

entertainment

author：comprehensive 2025-09-30 11:58:40 - browse：2

A phone screen displays the webpage of Medicare.gov — coverage from STAT — Adobe

Over the past few weeks, Medicare Advantage insurers demanded that the Biden administration give them higher payment rates for next year. The government’s data on how much people were using health care didn’t match their own data, insurers and lobbyists griped — and therefore they wouldn’t be paid enough to cover those costs.

But the federal government was not persuaded by the industry’s data or lobbying push. The Biden administration and its Medicare agency decided to stick with their proposals from January on Monday, dealing a blow to an insurance industry that has come to rely on Medicare Advantage for a steady stream of profits.

The result: In 2025, right after a new president is elected, Medicare Advantage insurers will have to absorb a slight decrease of 0.2% to the baseline payment rates that insurers receive from the government for enrolling older adults and people with disabilities. The stock prices of the largest Medicare Advantage insurers — UnitedHealth, Humana, CVS Health, and Elevance Health — all fell by at least 4% in after-hours trading.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： First Opinion Podcast: What happens when kids become caregivers?

WSS

NIH director takes cautious approach to Biden drug pricing priority

Insmed lung disease drug hits target in key Phase 3 trial

Stigma and the return of syphilis

Prior authorization will have to move faster under new Biden rule

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

NIH director takes cautious approach to Biden drug pricing priority

leisure time

entertainment

entertainment

Malaria cases in Florida and Texas: Here’s what you need to know

Copay coupons to count toward deductibles, after Biden court move

Peter Hotez and the public health issue of online harassment

FDA clears AI tool for detecting skin cancer

Moonlake's readout produced a cash windfall. Risks remain

Elizabeth Holmes banned from government health programs

Continuity nursing helped my family in our darkest PICU moments

How digital therapeutics firms are pivoting after Pear's bankruptcy

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

knowledge

iTeos Therapeutics debuts first data on TIGIT

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Readout Newsletter: Merck, J&J, and long Covid

Do more moles mean more problems? Not so, says new study

Eli Lilly, Pfizer, and others want in on the online prescription market

Research misconduct: Proposed new rules face resistance

hotspot

explore

entertainment

focus